Skip to main content
. 2009 Jun 8;8:127. doi: 10.1186/1475-2875-8-127

Figure 2.

Figure 2

Effect of initial efficacy on cost-effectiveness of BSV by transmission setting and delivery modality. Results obtained assuming a vaccine half-life of 10 years, homogeneity value of 10, and vaccine price of US$2. EPI & Campaigns means EPI with 70% mass vaccination.